Multi-Tracer PET Assessment of Primary Brain Tumors

Summary

The standard treatment approach for patients with high-grade primary brain tumors includes maximum feasible surgical resection, followed by 6 weeks of concurrent cranial irradiation and daily low-dose temozolomide chemotherapy, followed by 12 cycles of high-dose temozolomide administered for 5 consecutive days every 4 weeks \[Stupp 2005\]. Contrast-enhanced MRI is the current standard for evaluating the success of therapy and monitoring for tumor recurrence. MRI is typically obtained prior to initial surgery, within 24 hours after surgery, at the conclusions of cranial irradiation, and then every 8 weeks during temozolomide chemotherapy until evidence of recurrence. Despite this careful clinical and radiographic surveillance, and despite decades of research into the histologic and molecular classification of primary brain tumors, our ability to predict tumor behavior remains very limited. Some gliomas will result in overall survival times of only months, whereas other histologically-identical gliomas may yield survivals of years to decades \[Carson 2007, Curran 1993, Lamborn 2004\]. Current assessment of tumor response to therapy is also poor. Patients with complete radiographic response after cranial irradiation often progress rapidly post-irradiation. In contrast, some patients with enhancing masses at the end of chemoradiotherapy may respond dramatically to further chemotherapy alone, or the masses may even disappear in the absence of further therapy (so called "tumor pseudoprogression") \[Chamberlain 2007\]. This confounding situation demonstrates a need for better assessment of tumor response.

Conditions

• Brain Tumors
• Cancer

Interventions

DRUG

[18F]fluoro-2-deoxy-D-glucose (FDG)

Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.

DRUG

3'-deoxy-3'-[18F]fluorothymidine (FLT)

Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors

DRUG

[15O]-H2O

Brain scan with imaging agent to determine tumor blood flow

DRUG

[11C]Acetate

Brain scan with imaging agent to determine growth activity of tumor

Sponsors & Collaborators

• University of Utah

  lead OTHER

Principal Investigators

• John M Hoffman, MD · Huntsman Cancer Institute

• Daniel Kadrmas, PhD · Huntsman Cancer Institute

• Randy Jensen, MD,PhD · Huntsman Cancer Institute

• Howard Colman, MD,PhD · Huntsman Cancer Institute

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-11-12

Primary Completion

2015-02-03

Completion

2015-02-03

FDA Drug

Yes

Countries

• United States

Study Locations